Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC |
Contreras JaimeSenior Vice President
|
SaleCommon shares without par value | 500 | $52.03 | $26,015.00 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 13 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,739 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC |
Contreras JaimeSenior Vice President
|
SaleCommon shares without par value | 200 | $52.03 | $10,405.00 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 12 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,239 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC |
Contreras JaimeSenior Vice President
|
SaleCommon shares without par value | 1,600 | $52.02 | $83,232.00 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 11 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,439 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC |
Contreras JaimeSenior Vice President
|
SaleCommon shares without par value | 3,816 | $52.01 | $198,470.16 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 10 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,039 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC |
Contreras JaimeSenior Vice President
|
SaleCommon shares without par value | 1,109 | $52.00 | $57,668.00 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 9 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,855 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC |
Contreras JaimeSenior Vice President
|
SaleCommon shares without par value | 909 | $51.99 | $47,258.91 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 8 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,964 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC |
Contreras JaimeSenior Vice President
|
SaleCommon shares without par value | 1,913 | $51.98 | $99,437.74 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 7 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,873 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC |
Contreras JaimeSenior Vice President
|
SaleCommon shares without par value | 1,701 | $51.97 | $88,400.97 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,786 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC |
Contreras JaimeSenior Vice President
|
SaleCommon shares without par value | 4,152 | $51.96 | $215,737.92 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,487 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC |
Contreras JaimeSenior Vice President
|
SaleCommon shares without par value | 34,400 | $51.95 | $1,787,080.00 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,639 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionCommon shares without par value | 22,000 | $27.03 | $594,739.20 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 3 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionCommon shares without par value | 17,300 | $22.39 | $387,379.87 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 2 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionCommon shares without par value | 13,400 | $26.19 | $350,917.86 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC |
Fussell Stephen RExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 44,000 | $0.00 Strike: $27.03 | $0.00 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · derivative · entry 13 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 44,000 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC |
Fussell Stephen RExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 45,800 | $0.00 Strike: $22.39 | $0.00 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · derivative · entry 12 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 45,800 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC |
Fussell Stephen RExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 28,700 | $0.00 Strike: $26.19 | $0.00 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · derivative · entry 11 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 28,700 shares Expires 2020-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC |
Fussell Stephen RExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 38,700 | $0.00 Strike: $26.02 | $0.00 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · derivative · entry 10 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 38,700 shares Expires 2019-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC |
Fussell Stephen RExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 39,350 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · derivative · entry 9 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 39,350 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC |
Fussell Stephen RExecutive Vice President
|
SaleCommon shares without par value | 196,550 | $49.50 | $9,729,225.00 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · nonDerivative · entry 6 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,138 Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC |
Fussell Stephen RExecutive Vice President
|
Exercise / conversionCommon shares without par value | 44,000 | $27.03 | $1,189,478.40 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · nonDerivative · entry 5 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC |
Fussell Stephen RExecutive Vice President
|
Exercise / conversionCommon shares without par value | 45,800 | $22.39 | $1,025,549.02 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC |
Fussell Stephen RExecutive Vice President
|
Exercise / conversionCommon shares without par value | 28,700 | $26.19 | $751,592.73 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC |
Fussell Stephen RExecutive Vice President
|
Exercise / conversionCommon shares without par value | 38,700 | $26.02 | $1,006,780.50 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC |
Fussell Stephen RExecutive Vice President
|
Exercise / conversionCommon shares without par value | 39,350 | $26.70 | $1,050,538.76 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2017 Filed Aug 22, 2017 21:04 UTC |
LIDDY EDWARD MDirector
|
PurchaseCommon shares without par value | 1,185 | $48.96 | $58,012.39 |
DisclosureSEC source: 0001179110-17-011737 · edgar.xml · nonDerivative · entry 1 LIDDY EDWARD M · CIK 0001188983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,967 Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 21:20 UTC |
STARKS DANIEL JDirector
|
Exercise / conversionOption (right to buy) · Derivative | 336,131 | $0.00 Strike: $33.14 | $0.00 |
DisclosureSEC source: 0001179110-17-011054 · edgar.xml · derivative · entry 5 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 336,131 shares Expires 2018-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: St. Jude Medical, Inc. stock option that was converted to an Abbott stock option in connection with Abbott's acquisition of St. Jude Medical, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 21:20 UTC |
STARKS DANIEL JDirector
|
Exercise / conversionOption (right to buy) · Derivative | 168,413 | $0.00 Strike: $28.50 | $0.00 |
DisclosureSEC source: 0001179110-17-011054 · edgar.xml · derivative · entry 4 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 168,413 shares Expires 2018-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: St. Jude Medical, Inc. stock option that was converted to an Abbott stock option in connection with Abbott's acquisition of St. Jude Medical, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 21:20 UTC |
STARKS DANIEL JDirector
|
Exercise / conversionCommon shares without par value | 336,131 | $33.14 | $11,139,381.34 |
DisclosureSEC source: 0001179110-17-011054 · edgar.xml · nonDerivative · entry 2 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,943,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 21:20 UTC |
STARKS DANIEL JDirector
|
Exercise / conversionCommon shares without par value | 168,413 | $28.50 | $4,799,770.50 |
DisclosureSEC source: 0001179110-17-011054 · edgar.xml · nonDerivative · entry 1 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,607,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 21:14 UTC |
Bracken Sharon JSenior Vice President
|
SaleCommon shares without par value | 1,000 | $49.16 | $49,161.00 |
DisclosureSEC source: 0001179110-17-011052 · edgar.xml · nonDerivative · entry 3 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,206 Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 21:14 UTC |
Bracken Sharon JSenior Vice President
|
SaleCommon shares without par value | 600 | $49.16 | $29,496.00 |
DisclosureSEC source: 0001179110-17-011052 · edgar.xml · nonDerivative · entry 2 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,206 Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 21:14 UTC |
Bracken Sharon JSenior Vice President
|
SaleCommon shares without par value | 400 | $49.17 | $19,666.00 |
DisclosureSEC source: 0001179110-17-011052 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,806 Read SEC document |
| July 27, 2017 Filed Jul 28, 2017 21:04 UTC |
Blaser Brian J.Executive Vice President
|
SaleCommon shares without par value | 15,000 | $50.00 | $750,000.00 |
DisclosureSEC source: 0001179110-17-010788 · edgar.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,154 Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 21:03 UTC |
ALLEN HUBERT LExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 4,600 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001179110-17-010741 · edgar.xml · derivative · entry 5 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 4,600 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 21:03 UTC |
ALLEN HUBERT LExecutive Vice President
|
SaleCommon shares without par value | 200 | $50.79 | $10,158.44 |
DisclosureSEC source: 0001179110-17-010741 · edgar.xml · nonDerivative · entry 4 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,879 Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 21:03 UTC |
ALLEN HUBERT LExecutive Vice President
|
SaleCommon shares without par value | 1,800 | $50.79 | $91,422.00 |
DisclosureSEC source: 0001179110-17-010741 · edgar.xml · nonDerivative · entry 3 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,079 Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 21:03 UTC |
ALLEN HUBERT LExecutive Vice President
|
SaleCommon shares without par value | 2,600 | $50.80 | $132,067.00 |
DisclosureSEC source: 0001179110-17-010741 · edgar.xml · nonDerivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,879 Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 21:03 UTC |
ALLEN HUBERT LExecutive Vice President
|
Exercise / conversionCommon shares without par value | 4,600 | $26.70 | $122,807.58 |
DisclosureSEC source: 0001179110-17-010741 · edgar.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 21:08 UTC |
BRYNELSEN CHARLESSenior Vice President
|
GrantOption (right to buy) · Derivative | 69,024 | $0.00 Strike: $50.74 | $0.00 |
DisclosureSEC source: 0001179110-17-010711 · edgar.xml · derivative · entry 2 BRYNELSEN CHARLES · CIK 0001712459 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,024 Underlying: Common shares · 69,024 shares Expires 2027-07-23 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,008 on 07/24/2018, 23,008 on 07/24/2019, and 23,008 on 07/24/2020. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 21:08 UTC |
BRYNELSEN CHARLESSenior Vice President
|
GrantCommon shares without par value | 9,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010711 · edgar.xml · nonDerivative · entry 1 BRYNELSEN CHARLES · CIK 0001712459 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,980 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 21:37 UTC |
Salvadori Daniel Gesua SiveSenior Vice President
|
GrantOption (right to buy) · Derivative | 49,611 | $0.00 Strike: $50.72 | $0.00 |
DisclosureSEC source: 0001179110-17-010659 · edgar.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,611 Underlying: Common shares · 49,611 shares Expires 2027-07-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,537 on 07/21/2018, 16,537 on 07/21/2019, and 16,537 on 07/21/2020. Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 21:37 UTC |
Salvadori Daniel Gesua SiveSenior Vice President
|
GrantCommon shares without par value | 7,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010659 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,285 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 22:00 UTC |
PEDERSON MICHAEL JSenior Vice President
|
GrantOption (right to buy) · Derivative | 69,024 | $0.00 Strike: $50.72 | $0.00 |
DisclosureSEC source: 0001179110-17-010666 · edgar.xml · derivative · entry 3 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,024 Underlying: Common shares · 69,024 shares Expires 2027-07-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,008 on 07/21/2018, 23,008 on 07/21/2019, and 23,008 on 07/21/2020. Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 22:00 UTC |
PEDERSON MICHAEL JSenior Vice President
|
GrantCommon shares without par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010666 · edgar.xml · nonDerivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,187 F2 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, vesting in annual increments of 3,334 on 07/21/2018, 3,333 on 07/21/2019, and 3,333 on 07/21/2020. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 22:00 UTC |
PEDERSON MICHAEL JSenior Vice President
|
GrantCommon shares without par value | 6,028 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010666 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,187 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 22:38 UTC |
Fain Eric SSenior Vice President
|
Tax withholdingCommon shares without par value | 1,524 | $50.84 | $77,480.16 |
DisclosureSEC source: 0001179110-17-010671 · edgar.xml · nonDerivative · entry 2 Fain Eric S · CIK 0001402222 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,046 Read SEC document |
| July 21, 2017 Filed Jul 25, 2017 22:38 UTC |
Fain Eric SSenior Vice President
|
Tax withholdingCommon shares without par value | 26,488 | $50.85 | $1,346,914.80 |
DisclosureSEC source: 0001179110-17-010671 · edgar.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 518,570 Read SEC document |
| July 21, 2017 Filed Sep 29, 2017 21:10 UTC Amendment |
Fain Eric SSenior Vice President
|
Disposition to issuerCommon shares without par value | 23,085 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-012768 · edgar.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,961 Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 22:44 UTC |
Bracken Sharon JSenior Vice President
|
GrantOption (right to buy) · Derivative | 35,730 | $0.00 Strike: $48.34 | $0.00 |
DisclosureSEC source: 0001179110-17-010338 · edgar.xml · derivative · entry 3 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,730 Underlying: Common shares · 35,730 shares Expires 2027-07-09 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,910 on 7/10/2018, 11,910 on 7/10/2019, and 11,910 on 7/10/2020. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 22:44 UTC |
Bracken Sharon JSenior Vice President
|
GrantCommon shares without par value | 5,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010338 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,206 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.